Full Text Journal Articles by
Author Hesham S Al Sallami

Advertisement

Find full text journal articles








Identifying the core concepts of pharmacology education.

Paul J White, Elizabeth A Davis, Marina Santiago, Tom Angelo, Alison Shield, Anna-Marie Babey, Barbara Kemp-Harper, Gregg Maynard, Hesham S Al-Sallami, Ian F Musgrave, Lynette B Fernandes, Suong N T Ngo, Tina Hinton,

Pharmacology education currently lacks an agreed knowledge curriculum. Evidence from physics and biology education indicates that core concepts are useful and effective structures around which such a curriculum can be designed to facilitate student learning. Building on previous work, we developed a novel, criterion-based method to identify the core concepts ... Read more >>

Pharmacol Res Perspect (Pharmacology research & perspectives)
[2021, 9(4):e00836]

Cited: 0 times

View full text PDF listing >>



Reduction of quantitative systems pharmacology models using artificial neural networks.

Abdallah Derbalah, Hesham S Al-Sallami, Stephen B Duffull,

Quantitative systems pharmacology models are often highly complex and not amenable to further simulation and/or estimation analyses. Model-order reduction can be used to derive a mechanistically sound yet simpler model of the desired input-output relationship. In this study, we explore the use of artificial neural networks for approximating an input-output ... Read more >>

J Pharmacokinet Pharmacodyn (Journal of pharmacokinetics and pharmacodynamics)
[2021, 48(4):509-523]

Cited: 1 time

View full text PDF listing >>



Advertisement

Authors' Reply to Friesen: "An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities".

Jaydeep Sinha, Hesham S Al-Sallami, Stephen B Duffull,

Clin Pharmacokinet (Clinical pharmacokinetics)
[2020, 59(10):1315]

Cited: 2 times

View full text PDF listing >>



The propagation of between-subject variability from dose to response.

Hesham S Al-Sallami, Daniel F B Wright, Stephen B Duffull,

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



An Extension of Janmahasatian's Fat-Free Mass Model for Universal Application Across Populations of Different Ethnicities.

Jaydeep Sinha, Hesham S Al-Sallami, Stephen B Duffull,

<h4>Background</h4>Fat-free mass (FFM)-based dose scaling is increasingly being adopted in clinical pharmacology. Given the complexities with the measurement of FFM in clinical practice, choosing an appropriate equation for FFM is critical for accurate dose scaling. Janmahasatian's FFM model (FFM<sub>Jan</sub>) has largely remained the preferred choice because of its mechanistic basis and ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2020, 59(9):1161-1170]

Cited: 1 time

View full text PDF listing >>



Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass.

Jaydeep Sinha, Stephen B Duffull, Bruce Green, Hesham S Al-Sallami,

<h4>Background</h4>Fat-free mass has gained wide acceptance as a scaler of the maintenance dose rate in obese patients. The choice of fat-free mass as a size scaler for the maintenance dose rate is based on its relationship with drug clearance, on the basis that only lean tissue is sufficiently metabolically active ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2020, 59(4):475-483]

Cited: 0 times

View full text PDF listing >>



Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine.

Jaydeep Sinha, Stephen B Duffull, Bruce Green, Hesham S Al-Sallami,

<h4>Background</h4>In vitro-in vivo extrapolation (IVIVE) of hepatic drug clearance (<i>CL</i>) involves the scaling of hepatic intrinsic clearance (<i>CL</i><sub>int,uH</sub>) by functional liver size, which is approximated by total liver volume (<i>LV</i>) as per the convention. However, in most overweight and obese patients, <i>LV</i> includes abnormal liver fat, which is not thought ... Read more >>

Curr Drug Metab (Current drug metabolism)
[2020, 21(10):746-750]

Cited: 0 times

View full text PDF listing >>



Pharmacometrics in Australasia-Twenty Years of Population Approach Group of Australia and New Zealand.

Stefanie Hennig, Jacqueline A Hannam, Carl M J Kirkpatrick, Christine E Staatz, Sam Holford, Stephen B Duffull, Hesham S Al-Sallami, Bruce G Charles, Nick Holford, David J R Foster,

CPT Pharmacometrics Syst Pharmacol (CPT: pharmacometrics & systems pharmacology)
[2019, 8(10):701-704]

Cited: 1 time

View full text PDF listing >>



Insulin pump initiation and education for children and adolescents - a qualitative study of current practice in New Zealand.

Yasmin H AbdulAziz, Hesham S Al-Sallami, Esko Wiltshire, Jenny Rayns, Jinny Willis, Joanna McClintock, Natalie Medlicott, Benjamin J Wheeler, ,

Purpose:Worldwide, the use of insulin pumps for the management of type 1 diabetes is increasing. There are no national or international published guidelines and few guidance recommendations detailing the education and training required to commence insulin pump therapy. The aim of this study is to describe current clinical practice regarding ... Read more >>

J Diabetes Metab Disord (Journal of diabetes and metabolic disorders)
[2019, 18(1):59-64]

Cited: 2 times

View full text PDF listing >>



Newborn Vitamin K Prophylaxis: A Historical Perspective to Understand Modern Barriers to Uptake.

Atif Majid, Miranda Blackwell, Roland S Broadbent, David P Barker, Hesham S Al-Sallami, Liza Edmonds, Nikki Kerruish, Benjamin J Wheeler,

Since its initial discovery almost a century ago, vitamin K has been labeled as both lifesaving and malignancy causing. This has led to debate of not only its use in general but also regarding its appropriate dose and route. In this article, we review through a historical lens the past ... Read more >>

Hosp Pediatr (Hospital pediatrics)
[2019, 9(1):55-60]

Cited: 2 times

View full text PDF listing >>



Choosing the Allometric Exponent in Covariate Model Building.

Jaydeep Sinha, Hesham S Al-Sallami, Stephen B Duffull,

<h4>Background</h4>Allometric scaling is often used to describe the covariate model linking total body weight (WT) to clearance (CL); however, there is no consensus on how to select its value.<h4>Objectives</h4>The aims of this study were to assess the influence of between-subject variability (BSV) and study design on (1) the power to ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2019, 58(1):89-100]

Cited: 6 times

View full text PDF listing >>



The influence of patient variables on insulin total daily dose in paediatric inpatients with new onset type 1 diabetes mellitus.

Marion Muller, Benjamin J Wheeler, Miranda Blackwell, Mathilde Colas, David M Reith, Natalie J Medlicott, Hesham S Al-Sallami,

Purpose:Insulin dose requirements at new diagnosis of type 1 diabetes mellitus (T1DM) vary widely. Current guidelines recommend an initial total daily dose (TDD) ranging from 0.5 to 1.0 IU/kg/day. It often takes several days of frequent dose adjustments before an optimal insulin dose is achieved. The aim of this study was ... Read more >>

J Diabetes Metab Disord (Journal of diabetes and metabolic disorders)
[2018, 17(2):159-163]

Cited: 0 times

View full text PDF listing >>



A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass.

Jaydeep Sinha, Stephen B Duffull, Hesham S Al-Sallami,

Fat-free mass (FFM) represents the lean component of the body devoid of fat. It has been shown to be a useful predictor of drug dose requirements, particularly in obesity where the excess fat mass does not contribute to drug clearance. However, measuring FFM involves complex and/or expensive experimental methodologies that ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2018, 57(7):781-795]

Cited: 3 times

View full text PDF listing >>



Insulin regimens for newly diagnosed children with type 1 diabetes mellitus in Australia and New Zealand: A survey of current practice.

Dharrshinee Selvakumar, Hesham S Al-Sallami, Martin de Bock, Geoffrey R Ambler, Paul Benitez-Aguirre, Esko Wiltshire, Elaine Tham, Peter Simm, Louise S Conwell, Phillipa J Carter, Benjamin B Albert, Jinny Willis, Benjamin J Wheeler, ,

<h4>Aim</h4>There is no consensus on the optimal insulin treatment for children newly diagnosed with type 1 diabetes mellitus (T1DM). The aims of this study were (i) to describe the insulin regimens used at diagnosis by patient age and geographical region and (ii) to explore differences between and within Australia (AU) ... Read more >>

J Paediatr Child Health (Journal of paediatrics and child health)
[2017, 53(12):1208-1214]

Cited: 2 times

View full text PDF listing >>



Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand.

June M Tordoff, Nagham J Ailabouni, Dorothy P Browne, Hesham S Al-Sallami, Andrew R Gray,

<h4>Unlabelled</h4>Background Despite warnings of possible serious events, and reports of little benefit, antipsychotic agents are commonly prescribed in residential care for older people with dementia. A residential care provider (RCP) in New Zealand sought to examine and improve prescribing in some of their facilities. Objective To examine changes following a ... Read more >>

Int J Clin Pharm (International journal of clinical pharmacy)
[2016, 38(4):941-949]

Cited: 1 time

View full text PDF listing >>



Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.

Hesham S Al-Sallami, Natalie J Medlicott,

<h4>Objectives</h4>Enoxaparin is a low-molecular weight heparin (LMWH) widely used for the treatment of thrombosis and measured through a chromogenic assay (anti-Xa). The aim of this project was to investigate the impact of patient and sampling sources of variation on an anti-Xa assay for enoxaparin.<h4>Methods</h4>COATEST was used in accordance with manufacturer's ... Read more >>

J Pharm Pharmacol (The Journal of pharmacy and pharmacology)
[2015, 67(2):209-214]

Cited: 4 times

View full text PDF listing >>



Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.

Rebecca Negrulj, Armin Mooranian, Nigel Chen-Tan, Hesham S Al-Sallami, Momir Mikov, Svetlana Golocorbin-Kon, Marc Fakhoury, Gerald F Watts, Frank Arfuso, Hani Al-Salami,

We have demonstrated a permeation-enhancing effect of deoxycholic acid (DCA), the bile acid, in diabetic rats. In this study, we designed DCA-based microcapsules for the oral delivery of the antilipidemic drug probucol (PB), which has potential antidiabetic effects. We aimed to further characterize these microcapsules and examine their pH-dependent release ... Read more >>

Artif Cells Nanomed Biotechnol (Artificial cells, nanomedicine, and biotechnology)
[2016, 44(5):1290-1297]

Cited: 18 times

View full text PDF listing >>



Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment.

Armin Mooranian, Rebecca Negrulj, Hesham S Al-Sallami, Zhongxiang Fang, Momir Mikov, Svetlana Golocorbin-Kon, Marc Fakhoury, Frank Arfuso, Hani Al-Salami,

In previous studies carried out in our laboratory, a bile acid formulation exerted a hypoglycaemic effect in a rat model of type 1 diabetes (T1D). When the antidiabetic drug gliclazide was added to the bile acid, it augmented the hypoglycaemic effect. In a recent study, we designed a new formulation ... Read more >>

J Microencapsul (Journal of microencapsulation)
[2015, 32(2):151-156]

Cited: 13 times

View full text PDF listing >>



Between-subject variability: should high be the new normal?

Hesham S Al-Sallami, Song Lim Cheah, Shiou Yii Han, Joel Liew, Jin Lim, Mary Anne Ng, Hayneil Solanki, Run Jie Soo, Victoria Tan, Stephen B Duffull,

Eur J Clin Pharmacol (European journal of clinical pharmacology)
[2014, 70(11):1403-1404]

Cited: 6 times

View full text PDF listing >>



Is the dose of dabigatran really more predictable than warfarin?

Daniel F B Wright, Hesham S Al-Sallami, Stephen B Duffull,

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2013, 76(6):997-998]

Cited: 2 times

View full text PDF listing >>



Dabigatran: rational dose individualisation and monitoring guidance is needed.

Stephen B Duffull, Daniel F B Wright, Hesham S Al-Sallami, Paul J Zufferey, James M Faed,

Dabigatran is the first oral anticoagulant to be introduced in New Zealand without prescribing restrictions for over 50 years. Not surprisingly, the drug has created a great deal of interest amongst health care providers as well as the general public and media. There seems to be a general feeling that ... Read more >>

N Z Med J (The New Zealand medical journal)
[2012, 125(1357):148-154]

Cited: 8 times

View full text PDF listing >>



The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model.

Daniel F B Wright, Venkata V Pavan Kumar, Hesham S Al-Sallami, Stephen B Duffull,

The aim of this study was to explore the influence of simvastatin dosing time, variable compliance and circadian cholesterol production on the reduction of low-density lipoprotein (LDL). A published pharmacokinetic-pharmacodynamic (PKPD) model for simvastatin was identified and evaluated. A model for circadian LDL production was incorporated into the PKPD model. ... Read more >>

Basic Clin Pharmacol Toxicol (Basic & clinical pharmacology & toxicology)
[2011, 109(6):494-498]

Cited: 5 times

View full text PDF listing >>



Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins.

Hesham S Al-Sallami, Michael A Barras, Bruce Green, Stephen B Duffull,

Low-molecular-weight heparins are anticoagulants used in the treatment of thrombosis. They have effectiveness and safety profiles similar to those of unfractionated heparin but are considered an attractive alternative because of their predictable pharmacokinetic characteristics. In this article, we demonstrate the need for therapeutic monitoring of low-molecular-weight heparins by addressing evidence ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2010, 49(9):567-571]

Cited: 6 times

View full text PDF listing >>



The time course of drug effects.

Hesham S Al-Sallami, Venkata V Pavan Kumar, Cornelia B Landersdorfer, Jurgen B Bulitta, Stephen B Duffull,

This review aims to introduce the concepts and principles underpinning the time course of drug effects. Models describing the time course of drug concentrations (pharmacokinetic models) and the ensuing concentration-effect (pharmacodynamics models) as well as the linked time-effect (pharmacokinetic-pharmacodynamic models) are introduced. Different types of drug time-effects models are discussed ... Read more >>

Pharm Stat (Pharmaceutical statistics)
[2009, 8(3):176-185]

Cited: 10 times

View full text PDF listing >>





Advertisement

Disclaimer
0.995 s